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Abstract 
 
The activity of mTOR can be measured by looking at its marker: the phosphorylated ribosomal S6 kinase (p-
P70S6K). The effect of resveratrol on mTOR activity has been experimentally determined in normal TSC+/+ and 
mutated TSC-/- MEF’s cells, the mutation led to permanently activated mTOR. Cells have been treated with 
10µM and 30µM solution of resveratrol and 0,1µM solution of rapamycin for 24h and 48h. Rapamycin has been 
used as a reference. Western Blot technique has been use to quantify the amount of p-P70S6K in the different 
treatments. β-actin has been used as loading control. A significant difference in the β-actin content in almost all 
of the gels has been observed. This difference has complicated the quantification of the bands. 
In TSC-/- cells no conclusion can be made because the possible effect of resveratrol was masked by the high 
yield of protein. The effect of resveratrol on mTOR was detected in TSC+/+ cells where a reduction in the 
content of p-P70S6K was observed. After 24h and 10µM resveratrol treatment the measured reduction in the 
protein content was from 14% to 47% and for 30µM resveratrol treatment the measured protein reduction was 
from 17% to 83%. There is a significant difference in the values but this difference can be associated to the 
experimental error of the method. No enough data was obtained for 48h treatment, so no solid conclusion can 
be made. However in one experiment for the 10µM resveratrol treatment it is possible to observe a reduction 
in the protein content of 30% and for the 30µM resveratrol treatment the reduction was of 55%. That is the 
same reduction tendency observed in the 24h treatment. It is possible to observe an effect of resveratrol on 
the mTOR activity after 24h treatment, however it cannot be related in a time dependent manner since no 
differences has been observed between 24h and 48h treatment. 
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1. Introduction 
 
Tuberous Sclerosis Complex (TSC) is a multisystem disorder affecting the brain, skin, eyes, heart, lungs and 
kidneys caused by inactivating mutations in tumor suppressor genes TSC1 or TSC2. The mutation affects either 
TSC1 or TSC2 but never both at the same time. The TSC1 genes encode the protein hamartin and the TSC2 
genes encode the protein tuberin. Hamartin forms a regulatory complex with tuberin to negatively regulate the 
RAS homolog expressed in brain (Rheb).  TSC1 and TSC2 inhibit the function of the mammalian target of 
rapamycin (mTOR) through activation of the GTPase activity of Rheb (Weber and Gutmann, 2012).  
mTOR is a serine/threonine protein kinase and it belongs to the phosphatidylinositol kinase (PIKK) family with a 
molecular weight of ~280kDa. In the last decade it has drawn much attention because its fundamental function 
in cell proliferation and human tumorigenesis. Two different complexes of mTOR has been identified, mTORc1 
rapamycin-sensitive which has an essential rol in cell growth, and mTORC2 rapamycin-insensitive which 
function is not as well understood but has been related with the control of the cytoskeleton and the shape of 
the cell (Wullschleger, et al., 2006). 
 The understanding of the inhibition mechanism of the mTOR complex is of major interest for controlling cell 
proliferation. Mutation in TSC1 and TSC2 blocks the inhibitory effect of the tuberin/hamartin complex. The 
inhibition of this complex results in a continuously activated mTOR complex leading to the phosphorylation of 
the downstream effectors like the ribosomal S6 kinase and the elongation factor binding protein 4E-BP1, the 
consequence of the permanent activation of these two effectors is an uncontrolled cell growth and potential 
risk of tumorigenesis  (Napolioni and Curatolo, 2008). By finding components that can inhibit mTOR in a 
controlled and know-how way it would be possible to find medical application related uncontrolled cell growth, 
i.e. cancer.  
Resveratrol, a natural occurring poly-phenol found in wine, has been investigated for preventing carcinogenesis 
and for  increase longevity in some organism (Smoliga, et al., 2012). Recent studies claims that resveratrol 
potentiates the inhibitory effect of rapamycin thus having a therapeutic value for cancer treatment (He, et al., 
2011).  
In this project the long-term exposure effect of resveratrol on the mTOR complex of TSC2+/+ and TSC2-/- MEF 
(Mouse Embryo Fibroblasts) cells will be studied by looking at the phosphorylated ribosomal S6 kinase (p-
P70S6K) by using Western Blot technique. 
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2. Problem formulation 
 
The effect of resveratrol in the activity of the mTOR complex has been the subject for many studies world-
wide. At the NSM Institute of Roskilde University some studies had been carried on in order to determine. 
These studies have tried to reveal the effect of resvesatrol in mTOR activity by measuring the phosphorylated 
S6K (p-P70S6K), however cells have been treated with resveratrol for a short period of time (30min) and no 
much is known about the effect of resveratrol after a long term treatment.  
The aim of this project is to elucidate the effect of resveratrol in the activity of the mTOR after long-term 
exposure treatments. The study will focus on the effect of resveratrol in the mTOR activity after a long-time 
exposure to resveratrol. Two strains of MEF cells (TSC+/+ and TSC-/-) will be used. Wild type TSC+/+ cells will 
have normal biological activity while TSC-/- cells have a mutation that will keep mTOR constantly activated, a 
higher yield of protein  would be expected in mutants compared wild type. TSC+/+ and TSC-/- will be treated 
for 24 and 48 hours with a 10µM and 30µM solution of resveratrol. The activity of the mTOR will be assessed 
by the p-P70S6K protein content determination in treated cells byWestern Blot technique. 
3. Frame of the project 
 
In this project the effect of resveratrol on the activity of mTOR will be determined by looking at the 
phosphorylated ribosomal protein S6 kinase (p-P70S6K). TSC+/+ and TSC-/- MEF cells will be used for doing this 
study. These cells will be exposed to different treatments including resveratrol and rapamycin. The protein 
determination will be done by Western Blot technique and the bands will be quantified by band analysis. Only 
the TSC-mTOR-P70S6K pathway will be treated in this project. The biological function of p-P70S6K will not be 
deeply detailed and other protein complexes or biological pathway will not be covered. Finally only the 
experimental results obtained from western blot analysis will be given and discussed in this project.  
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4. Background 
3.1 mTOR 
 
In this section mTOR is presented by giving a description of its composition and key function in cell metabolism. 
Furthermore, in the two next subsections, the two complexes of mTOR, mTORC1 and mTORC2 will be 
explained. 
The target for rapamycin (TOR) protein was discovered in the yeast Saccharomyces cerevisiae through mutants 
showing resistance to rapamycin. Until today TOR is present in almost all kind of eukaryotic cells, from yeast to 
mammals (Heitman, et al., 1991). It has a molecular weight of 280kDa and in humans is encoded by the FRAP1 
gene. 
 
The mammalian target for rapamycin (mTOR), also called mechanistic TOR, is a cellular complex responsible for 
many biological functions including the regulation between anabolic and catabolic reactions. The molecular 
structure of mTOR is complex, with different protein domains, as it is the consequence of its fine-tuning 
function as multi-regulated protein involved in different cellular pathways. In figure 1 it is possible to observe 
the different domains. Each domain has a specific function.  
 
Different environmental stimuli through different upstream and downstream signaling pathways can trigger 
mTOR activity resulting in cell proliferation. Cellular pathways are tightly regulated by many cofactors and 
effectors making mTOR an important piece of cellular regulation mechanism, by knowing these regulation 
mechanisms it would be possible to have a better understanding of mTOR cell function. Lately, mTOR has been 
subject of many scientific studies. Since in this project we will look at the p-P70S6K (kinase related to cell 
proliferation) especially relevant are the studies related mTOR and cancer prevention. Uncontrolled cell 
proliferation is the ultimate responsible for cancer. 
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Figure 1. mTOR 3-D structure.Tthe most relevant parts 
are the FAT domain in the N-terminus (blue part).  The 
mLST8 (gren) that binds to the kinase domain of mTOR 
KD C lobe (purple). The kinase domain N lobe (yellow) 
that binds to the FBR domain (red), binding site of the 
rapamycin-FKBP12 complex. In this picture the HEAT 
repeats are included in the FAT region (Yang, et al., 
2013). 
 
 
 
 
 
mTOR is a serine/theorine kinase protein member of the phosphoinositide 3-kinase family (PIKK). 
Like common for the PIKK family, mTOR has a number of HEATS repeats (huntingrin-elongation-Asubunit-TOR) 
in its N-terminus, HEAT repeats are responsible for protein-protein interactions (Chen, et al., 1995). It also 
contain the FAT domain, which is a three letter abbreviation of its containing proteins: FRAP (FKBP-rapamycin 
associated protein), ATM (Ataxia telangiectasia mutated) and TRRAP (transformation/transcription domain-
associated protein) and it is located between the FBR domain (FKPB-12-rapamycin complex) and the HEAT 
repeats. At the C-terminus it contains another FAT domain, the FATC domain (Bosotti, et al., 2000). The FAT 
and FATC interacts to yield a favorable configuration of mTOR for catalytic activity. A deletion of a single amino 
acid in the FATs domains suppresses the activity of mTOR (Peterson, et al., 2000). Just upstream the FAT 
domain is located the catalytic domain (Kinase domain). The main difference between mTOR and the other 
members of the PIKK family is the FRB domain (FKBP12 rapamycin binding domain).  
 
Rapamycin is an allosteric inhibitor of mTOR, and is not binding directly to mTOR, first it binds to FKBP12 
(FK506 binding protein 12), and then is the complex rapamycin-FKBP12 that binds to mTOR (figure 2). Some 
studies point out that rapamycin can still bind mTOR without FKBP12, but the binding affinity decrease 100-
1000 folds (Meric-Bernstam and Gonzalez-Angulo, 2009). 
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Figure 2. Structure of mTOR, the most relevant parts are the HEAT repeats in the N-terminus, binding site for Raptor and Rictor. Deptor 
binding site at FAT domain. And the binding site of the rapamycin-FKBP12 complex (Martelli, et al., 2010).  
 mTOR is found in two protein complexes, mTOR complex 1 (mTORC1) and mTORC2. The two complexes have 
some similar effectors and some others are different and characteristic for each of the complexes.  
3.1.1 mTORC1 
 
mTORC1 is composed of the proteins mTOR, Raptor, mLST8, and the negative regulators PRAS40 and Deptor, 
figure 3. 
The main component of mTORC1 is the regulatory protein Raptor that binds to the HEATS repeats of mTOR. 
The interaction mTOR-Raptor is controlled by the mLST8 protein, a common protein in mTORC1 and mTORC2. 
mLST8 regulates the kinase activity of mTOR. In eukaryotic cells the substrate of mTORC1 are initiation factors 
4E-binding proteins, and the P70S6 kinases (Brown, et al., 1995). Ribosomal S6 kinase regulates cell 
proliferation and in order to be fully activated it needs to be phosphorylated by mTORC1 (Fingar, et al., 2002).  
 
The proline rich Akt substrate (PRAS40) is also a component of mTORC1, some studies describe PRAS40 as 
mTORC1 substrate inhibitor (Sancak, et al., 2007). mTOR kinase activity to insulin was associated with the 
increasing binding of 4EBP1 to Raptor. However during specific cell process PRAS40 has a higher binding affinity 
for Raptor, decreasing the binding affinity with 4EBP1 and thus decreasing the kinase activity of mTOR (Wang, 
et al., 2007). The function of PRAS40 as inhibitor is not the only function associated to this protein. In some 
other studies PRAS40 is considered a substrate for mTORC1 (Oshiro, et al., 2007) and in others it is stated that 
PRAS40 has both functions (Thedieck, et al., 2007). Deptor (DEP domain-containing mTOR-interacting protein) 
is an mTOR binding protein that inhibits mTORC1 and mTORC2. Deptor expression is negatively regulated by 
mTORC1 and mTORC2. It has been found that Deptor bind directly with mTOR and not with mLST8, the other 
common protein between mTORC1 and mTORC2. Low levels of Deptor activate the S6K promoting cell growth 
and mTOR kinase activity. On the other hand Deptor overexpression reduces S6K activiy. It is special relevant in 
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studies with cancer cells where Deptor levels are low. Deptor is encoded in humans by the DEPTOR gene 
(Peterson, et al., 2009). 
The biological function of mTORC1 is regulated by the associated protein Rheb which activates mTORC1 when 
is GTP-bounded, Rheb is at the same time regulated by the Tuberous Sclerosis Complex (TSC1 and TSC2) (Inoki, 
et al., 2003).  TSC1 and TSC2 control the switch between GTP-GDP states of Rheb. When Rheb is in its GTP-
bound state mTOR is activated and when it is in the GDP-state mTOR is inhibited (Zhang, et al., 2003). TSC1 and 
TSC2 are targets for many signaling pathway and its function in cell metabolism is directly related with the 
function of mTORC1.  
By using different energy sources  mTORC1 is the responsible for the translation of key proteins relevant for 
cell proliferation and growth. 
Figure 3. Associated multi-components in mTORC1 
reflect the complexity of mTOR regulation 
mechanism in cell growth. mTORC1  is composed by 
mTOR, mLST8 and Deptor in the same way mTORC2 
is, but Raptor and PRAS40 are mTORC1 characteristic 
associated proteins. This picture has been 
manipulated from the original document (Chong and 
Maiese, 2012). 
 
3.1.2. mTORC2 
 
The mTORC2, the second complex of mTOR is composed of Rictor, mLST8, mSIN1, Deptor and Protor-1, figure 
4. Opposite than mTORC1, mTORC2 is rapamycin insensitive because rapamycin cannot bind to it. However 
long term treatment with rapamycin seems to lead to the dissociation of mTORC2 through the 
dephosphorylation of Rictor and mSIN1 (Rosner and Hengstschlager, 2008). It has been pointed out that 
mTORC2 function upstream of Rho GTPases and is responsible for cell cytoskeleton organization (Jacinto, et al., 
2004). Furthermore mTORC2 complex is the responsible of the phosphorylation of Ser473 in the Akt protein 
kinase (Sarbassov, et al., 2005) through mSIN1 activity, necessary for assembling mTORC2 and for its capacity 
to phosphorylate Akt (Frias, et al., 2006). Rictor, rapamycin-insensitive companion of mTOR, is protein encoded 
in humans by the RICTOR gene. Rictor and mSIN1 stabilized each other giving a more structural integrity to 
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mTORC2 (Frias, et al., 2006). Furthermore Rictor regulates the expression of Protor-1 (also called PRR5). The 
biological function of Protor-1 is not completely elucidated. Recent studies suggest that Protor-1 has a function 
in the activation of specific kinases, for example, in the liver Protor-1 enables mTORC2 to activate SGK1 
(Pearce, et al., 2011). 
 
 Deptor, a mTOR- interacting protein, negatively regulates both mTORC1 and mTORC2, as previously explained. 
The mLST8 (mammalian lethal with SEC13 protein 8) protein is necessary for the Raptor-mTOR interaction 
while it is not necessary to maintain the Rictor-mTOR interaction. Rictor and mLST8 are necessary for specific 
cell activities like phosphorylation of particular proteins like Akt/PKB while, on the other hand, is not important 
for other kind of phosphorylation like in S6K1 (Guertin, et al., 2006). That tells about the enormous degree of 
selectivity of mTOR complexes and regulation mechanism in cell activity pathways.   
 
Even though there is more information in the literature about mTORC1 than mTORC2, it is accepted that 
mTORC2 plays an important role in cell motility by the activation of Rho GTPases and cell survival by the 
phosphorylation of Akt kinase (Bracho-Valdes, et al., 2011). 
 
 
Figure 4. The cellular function of mTORC2 is not as well understood as in mTORC1. mTORC2 has Protor-1, mSIN1 and Rictor as 
characteristic associated proteins. mTOR, mLST8 and Deptor are in common with mTORC1. This picture has been manipulated from the 
original document (Chong and Maiese, 2012). 
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3.1.3 Relation between mTORC1 and S6K activity. 
 
Malfunction of mTORC1 leading to a permanently activated stage is observed in human cancer cells. mTOR 
complex is important in translation from mRNA to protein, when mTORC1 is not functioning correctly 
uncontrolled protein synthesis may occurs. This defect leads to cancer and a bad regulation of the cell 
proliferation. Continuously activated mTORC1 leads to a continued phosphorylation of the ribosomal protein 
S6 kinase (P70S6K). Phosphorylated P70S6K (p-P70S6K) is the responsible for signal transduction, mRNA 
translation and ribosomal production.  
The kinase activity of this protein is given by its capacity to add phosphate groups to the hydroxyl groups of the 
substrate amino acids (serine, thronine and tyrosine are the three amino acids with OH groups). 
Phosphorylation causes a change in the conformation of the protein and that is enough to open or close 
pockets where other proteins should be attached (Magnuson, et al., 2012).  
 
In mammals there are two homologs of the S6 kinase, the S6K1 and S6K2 isoform. S6. Ribosomal kinase S6K1 is 
encoded in humans by the RPS6K1 gene and is a 70kDa protein (therefore known as P70S6K). The P70S6K 
function in protein synthesis and in cell growth occurs during the G1 phase of the cell cycle (Montagne, et al., 
1999). 
3.2 PI3K/Akt/mTOR cascade 
 
The Akt-mTOR cascade is described in figure 7. Activation of mTORC-1 is the response to external cell signaling 
like glucose, amino acids, insulin or growth factors like IGF-1 (insulin growth factor 1), etc. One of the upstream 
activators of mTORC-1 is the PI3K (phosphatidylinositol 3 kinase), leading to a series of signal transduction 
inside the cell, known as the PI3K/Akt/mTOR/p70s6k pathway  (Stokoe, et al., 1997). In the presence of growth 
factors PI3K, mediating intermediate steps, attract to the plasma membrane the phosphoinosidite-dependent 
kinase 1 (PDK1) which phosphorylates Akt, a serine/threonine protein kinase (phosphatidilinositol regulated 
protein kinase) on the Thr308, figure 5 (Matsui, et al., 2003). However for full activation Akt should be aslo 
phosphorylated at the Ser473 residue and this is done by mTORC-2 (Manning and Cantley, 2007). Activated Akt 
inhibits TSC2 by phosphorylation. Repression of TSC1/TSC2 allows Rheb to accumulate in the GTP-bound state. 
Rheb-GTP bounded state activates mTORC1 signalling by a not yet completely elucidated mechanism (Martelli, 
et al., 2010). In addition to that Akt phosphorylates PRAS40 as well, when no phosphorylated PRAS40, as 
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mentioned before, it inhibits mTOR interaction with its substrates, so by this Akt also activates mTOR signaling 
(Wang, et al., 2008). 
 
Figure 5. Activated PI3K moves to the 
membrane and converts the plasma-membrane 
lipid phosphatidylinositol-4, 
5-bisphosphate (PtdIns(4,5)P2, PIP2) to 
phosphatidylinositol-3,4,5-trisphosphate 
(PtdIns(3,4,5)P2, PIP3). PIP3 attach Akt and its 
activator PDK1 to the membrane and Akt is 
activated by phosphorylation. The picture is a 
modification of the original one (Zhu and 
Nelson, 2012). 
 
 
 
 
Activated mTOR has two main downstream messengers, the ribosomal S6K and the eukaryotic translation 
initiation factor 4E-binding protein (4E-BP1). Phosphorylation of p70S6K by mTOR leads to a phosphorylation of 
the 40S ribosomal protein S6, and this activates protein translation (Chen, 2004). Before phosphorylation by 
mTOR the p70S6 kinase has to be pre-activated by phosphorylation of the Ser411, Ser418, Thr421, Ser424  and Ser371 
residues, is only in this pre-activated state when the Thr389 residue is available for phosphorylation by mTOR, 
figure 6. There is an important difference in the conformational change between the two states of the S6 
kinase (phosphorylated and no-phosphorylated). When no phosphorylated the two linker domains of the S6 
kinase are in contact. When mTOR phosphorylates the kinase at the Thr389 residue the two domains are clearly 
separated. This new conformational change in the activated kinase may be the responsible for further 
biological functions.  
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Figure 6. p70S6K pre-activation requires the phosphorylation of the Ser411, 
Ser418, Thr421, Ser424  and Ser371 located in the linker domain, these previous 
phosphorylations open the kinase domains and the new phosphorylation in 
Thr
389
 by mTOR is possible. Once Thr
389
 is phosphorylated the two domains 
of the kinase are separated and the last phosphorylation in the Thr229 is 
done by PDK1 (phosphoinositide-dependent protein kinase 1) leading to 
the finally activated p70S6K. Image modification from the article of Cayman 
chemical, Michigan 48108 USA, based on the PhD of Olivia May. 
https://www.caymanchem.com/app/template/Article.vm/article/2108 
 
 
 
 
 
However some studies with human muscle cells indicate that phosphorylation of p70S6k is not necessary 
related with the activation of mTOR (Fujita, et al., 2007). Furthermore other “in vitro” studies have questioned 
the dependence of mTOR in p70S6k phosphorylation (Holz and Blenis, 2005). 
A basic representation of the PI3K/Akt/mTOR/p70s6k pathway used in this project is presented in figure 7. 
 
Figure 7. External cell signals like growth factors contact specific 
receptors proteins in the cell membrane activating PI3K which by 
means of PIP3 phosphorylates Akt. Phosphorylated Akt inhibits the 
complexes TSC2/TSC1. That makes Rheb to accumulate in the GTP 
form which is necessary for mTOR activation. Once activated mTOR 
is the responsible of the phosphorylation of p70S6K.  
 
 
 
 
 
 
 
mTOR is involved in many other cellular pathways with many other co-factors and effectors,  in this report we 
have only explained the PI3K/Akt/mTOR/p70s6k   cascade since this is the relevant one for this project, having 
as an outcome the phosphorylation of the P70S6K.   
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3.3. Resveratrol 
 
Resveratrol (3,5,4-trihydroxistilbene) is a natural polyphenol compound isolated from the roots of the 
medicinal plant Polygonum Capsidatum back in 1963. Resveratrol is existing in cis and trans configuration and 
can be present in the skin of the grape berry, peanuts and pines. It is also present in red wine and not that 
much in white wine. Chemical structure of resveratrol is presented if figure 8. The interest behind this 
compound lays in its relative abundance in the dietary as well the many potential applications in the 
prevention of human diseases. Resveratrol biological application was first discovered as a fungicide synthetized 
by plants from p-coumaroyl-CoA and malonyl-CoA as a natural response against infections (Soleas, et al., 1997). 
 
Figure 8. Resveratrol can exist in two isomeric forms: the cis and trans configuration. The health benefits of resveratrol are documented 
for the trans-configuration. Isomeric trans-configuration of resveratrol is more stable than the cis-configuration, only stable at neutral 
pH and not indicated for the acidic environment present in the human stomach (Trela and Waterhouse, 1996). 
The biological effect of resveratrol is given by its polyphenolic structure. Polyphenols can have different 
biological functions mainly attributed to its antioxidant, metal-ion chelating and/or free radical scavenging 
activity (Ferguson, 2001). It has being discussed that resveratrol can modify the substrate-binding affinity of 
enzymes (Howitz, et al., 2003). Consequently the effect of Resveratrol in the different cell pathways can be 
explained from its ability to change the substrate-binding affinity of different enzymes involved in cellular 
activity.  
Some studies pointed out the cardiovascular protection effect of resveratrol as well its anti-inflammatory, anti-
aging and anticancer properties (Zhong, et al., 2012). 
One example of the anti-cancer properties of resveratrol is its role as an agonist for the estrogen receptor in 
human breast cancer cells. Resveratrol chemical structure is similar to the estrogen which also has phenolic 
rings. This similarity is crucial for explaining the biological effect of resveratrol.  In normal conditions estradiol 
binds to the estrogen-receptor of cells and transcription of specific genes present in human breast cancer cells 
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starts. Resveratrol inhibits the binding of estradiol to the estrogen-receptor decreasing the transcription level 
of carcinogenic genes (Gehm, et al., 1997). In figure 9 the molecular representation of the substrate-binding 
affinity of resveratrol is presented. Recent studies based on Aza-resveratrol analogs, a chemical modification 
that consist of including and aza group (H-C=N) between the two aromatic rings of resveratrol, with higher 
cytotoxic activity against breast cancer cells are being done in order to find therapeutic agents for commercial 
purposes. These studies confirm the bonding interaction of resveratrol with the estrogen receptor based on 
hydrogen bonding with the glutamate and arginine amino-acid residues of the estrogen-receptor (Siddiqui, et 
al., 2013). 
 
Figure 9. Resveratrol binding at the estrogen receptor β. The 
binding force is based on three strong hydrogen bonds with 
the glutamate and arginine amino-acid residues. Resveratrol 
is represented by the bold structure while the estrogen 
receptor structure is represented by thin lines. The hydrogen 
bonds are represented by dotted yellow lines. Image taken 
from VirtualToxLabTMService.  
 
 
 
 
From an anti-aging point of view resveratrol was reported to activate a sirtuin family of protein deacetylases. 
Overexpression of these proteins increased life span in yeast and flies, reseveratrol was investigated from a 
pharmacologic point of view (Tissenbaum and Guarente, 2001). However resveratrol has other molecular 
targets like the AMP-activated protein kinase (AMPK) which is also related with anti-aging pathways. AMPK 
function is to keep energy balance in cell by controlling carbon utilization and ATP production. Resveratrol 
activates AMPK and that increases the life span in nematodes (Apfeld, et al., 2004). Resveratrol and its 
application in the anti-aging field is under investigation and the next step is to determine the effect of 
resveratrol in humans cells and the possibility of develop a clinical application (Kaeberlein, 2010). 
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Resveratrol has being studied for its anticancer properties and it does it through multiple mechanisms like cell 
apoptosis, autophagy and necrosis. All together makes resveratrol an attractive molecule to be studied for its 
anti-carcinogenic properties and potential medical applications. 
However the study of the effect of resveratrol against cancer is not a simple task, the selected type of cell and 
the methodology is critical, furthermore results can vary significantly from “in vivo” and “in vitro” assays. In an 
“in vitro” experiment NuTu-19 ovarian cancer cells were drastically inhibited by resveratrol. During the same 
study in “in vivo” experiments shows no effect of resveratrol in the same NuTu-19 cells (Stakleff, et al., 2012).  
3.4.Rapamycin 
 
Rapamycin (generic name Sirulimus), was discovered in 1965 from the bacteria Streptomyces hygroscopicus  of 
the Easter Island (Rapa Nui) (Sehgal, et al., 1975). 
Rapamycin is a white crystal solid insoluble in water and soluble in almost all organic solvents, figure 10 
(Sehgal, 2003).  
 
Figure 10. Chemical structure of rapamycin. 
 
It has antibiotic properties against several strains of yeast and fungi, but no effect observed in gram-positive 
and gram-negative bacteria. However it has a strong antiproliferative and immunosupressant activity, and that 
gives to rampamycin his characteristic anti-cell proliferation activity.  
 
Rapamycin is a strong inhibitor of mTOR. Inhibtion of mTOR prevent phosphorylation of key enzmes for mRNA 
synthesis (i.e. P70S6K and 4E-BP1), without the translation of important mRNA cell cannot progress from the 
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G1 phase to the S phase. Therefore is known that rapamycin inhibits cell cycle at the G1 phase (Hidalgo and 
Rowinsky, 2000). The high binding affinity between rapamycin and FKBP-12 (FK506 binding protein 12) makes a 
strong rapamycin/FKBP-12 complex. This complex binds strongly with mTOR in its FRB domain. The 
consequence is a conformation change in mTOR, figure 11, and repression of specific downstream effectors like 
S6K (Brugarolas, et al., 2003). This inhibitory effect of mTOR has many applications in studies against cancer. 
 
Figure 11. Upper part (a) activated mTOR with 
the Kinase C (KC) lobe (pink) open and 
accessible for the phosphorylation of the S6K. 
FKBP-12/rapamycin complex (blue) has a high 
binding affinity with the FRB domain (red) of 
mTOR. (b) when binded, the FKBP-
12/rapamycin complex goes toward the 
mLST8 structure changing the mTOR 
configuration. The KC cleft narrow down 
leaving less space for the access of the S6K 
(Yang, et al., 2013). 
 
 
 
 
 
 
 
This inhibitory effect of mTOR has many applications in studies against cancer. Tuberous sclerosis complex 
(TSC) is a disorder caused by the inactivation of the tumor suppressor genes TSC1 and TSC2. These tumors may 
affect the central nervous system, kidney and lungs. Inactivated TSC1 and TSC2 genes lead to a continuously 
activated mTOR, and as explained before, different kinases responsible of cell growth and cell division will be 
activated as well. Therefore if rapamycin can directly inhibit mTOR activity, cell growth will be controlled even 
though malfunction of TSC genes.  One year and two year studies in patients with angiomyolipoma has been 
done with a reduction of the size of the tumor after rapamycin treatment (Bissler, et al., 2008). 
In addition to that it has been proved that rapamycin by inhibiting the phosphorylation of the p70S6k induces 
cell apoptosis by the activation of the apoptosis-signal regulating kinase 1 (ASK1) leading to different clinical 
trials for medical application (Jozwiak, et al., 2006).  
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Furthermore rapamycin has been studied for its effect against different disorders like Kaposi’s sarcoma, a 
tumor causes by the human virus herpesvirus-8, and it is attributed to its ability to reduce VEGF levels (vascular 
endothelial growth factor) after 1 month treatment (Stallone, et al., 2005).  
In breast cancer cells some studies indicate the possibility of using resveratrol in combination with rapamycin 
as an anti-cancer cocktail drug for enhanced results (He, et al., 2011). 
In a study with colorectal cancer cells it was observed a decreased level in cell proliferation when cells were 
treated with rapamycin. However not all the cell lines showed the same effect, some of the cells lines were not 
sensitive to rapamycin. That was explained in terms of biological differences between mTORC1 and mTORC2, 
mTORC1 is rapamycin sensitive while mTORC2 is not. In order to have a full knockdown of all the cell lines in 
colorectal cancer cells, inhibition of both mTORC1 and mTORC2 was done by using different inhibitors. 
mTORC1 was inhibited with rapamycin and mTORC2 was inhibited with a Rictor small interfering RNA (siRNA) 
(Gulhati, et al., 2009). That is a good example of the differences between mTORC1 and mTORC2 when 
considering treatments against cancer, different inhibitor may be used to knockdown both complexes.    
5. Methodology 
 
In this project we have used TSC-/- and TSC+/+ MEF’s cells treated with resveratrol. Determination of the 
phosphorylated and no phosphorylated P70S6K (abbreviated name p-P70S6K and P70S6K) and β-actin has 
been done mediating western immunoblotting. Cells have been lysed and total protein content determination 
has been done before western blot analysis. 
5.1 Experimental set-up 
The TSC-/- and TSC+/+ MEF’s cells were treated with resveratrol or the well-known mTOR inhibitor rapamycin. 
In each experiment both cell lines were tested for comparison. 
The TSC-/- and TSC+/+ MEF’s cells were treated with different treatments. A new cell culture was done for each 
of the experiment in order to evaluate the reproducibility of the results. The table below contains the 
description of the treatment for each of the cell lines (5 dishes for cell line). 
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Table1. Treatment overview 
Cells lines/Plates 1 2 3 4 5 
0% FBS Media + + + + + 
Control with DMSO  - + + + + 
10µM Resveratrol - - + - - 
30µM Resveratrol - - - + - 
0,1µM Rapamycin - - - - + 
 
Cells were incubated with the different treatments for 24h and 48h. In this project I will refer as an experiment 
the different cell treatments described in table 1 for both TSC+/+ and TSC-/- together the Western Blot 
analysis. So in this project 3 different experiments for 24h treatment, 2 different experiments for 48h, 1 
experiment for total P70S6K determination after 24h treatment and  1 experiment for total P70S6K 
determination after 48h treatment has been done. In total 7 experiment treatments with its corresponding 7 
Western Blot analysis has been done. 
 
5.2 Cell growth and cell lysate. 
 
1.0 x 106 TSC2+/+ or TSC2-/- cells were set up in 10cm dishes with 10mL 10% FBS media overnight to allow for 
attachment. Five dishes (according table 1) were set up per cell line. After overnight the overnighted media 
was substituted by 10mL of fresh media. Dish one contains cells control with DMSO. Dish one contains 0%FBS 
media (starved cells). Dish two contains the control cell with DMSO. Dish three contains cells treated with 
10µM resveratrol. Dish four contains cells treated with 30µM resveratrol, and dish five contains cell treated 
with rapamycin. Cells were incubated for 24h and 48h. 
After incubation cells were washed with 10mL PBS, thereafter cells were lysed with 0.5ml cold lysis buffer 
(40mM HEPES pH 7.5, 120mM NaCl, 1mM EDTA, 10mM Na-pyrophosphate, 10mM glycerophosphate, 50mM 
NaF, 0.3% CHAPS) with freshly added protease and phosphatase inhibitors. Cells were scraped off with a cell 
scrapper and collected in 1.5mL eppendorf tube and kept on ice.  Thereafter cells were sonicated twice for 5 
seconds on ice and centrifuged at 4000 x g in 4oC for 30 minutes. The supernatant was transferred to a new 
eppendorf tube and stored in -20oC for protein concentration determination and -80oC for western blot 
analysis. The protein content was determined by the Bio-Rad DC protein assay with an absorbance at 750nm as 
described by the manufacturer with a BSA standard curve.  
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5.3 Western blotting protocol 
 
Equal amounts of protein are mixed with 4µL loading buffer (1250µl 1M Tris-HCl, 1000 µl 25% Glycerol, 
200.5mg 325mM Dithiotreitol, 200mg 5.0% SDS, 10 µl of 10 % Bromophenol blue and 440 µl Milli Q water). The 
samples are heated at 70°C for 10 minutes. The gel is rinsed with miliQ water. Next the samples and pre-
stained molecular weight marker are added on the gel. Pre-running of gel is done at 60V for 30 minutes, 
thereafter at 120V for 1hour. 
In the meantime the PVDF membrane for is soaked in 10 minutes in 96% ethanol and afterwards in blotting 
buffer for 20 minutes. The sponges and filter papers are also soaked 20min in blotting buffer. After 
electrophoresis the gel is soaked in blotting buffer for 5 minutes. Thereafter the blotting sandwich is 
assembled.  
 
The blotting (also called transfer) was done by running one gel at 180mA. When working with two gels the 
blotting was done at 220mA for 1 hour until the markers can be clearly identified and are well separated. When 
the blotting is finished the membrane was cut in two parts. The upper part is for the determination of the p-
P70S6K or P70S6K and the lower part is used for the determination of the β-actin.  The upper part of the 
membrane is washed one time for 5 minutes in TBS-T (a mixture of Tris-Buffered Saline and Tween 20: 10mM 
Tris, 68mM NaCl, 1mL tween 20 in 1L miliQ water). The lower part of the membrane is washed one time for 5 
minutes in TBS-A (Tris-Buffered Saline: 50mM Tris, 151mM NaCl,  800mL Milli Q water, adjust to pH 10.5 with 
HCl, 1mL Tween 20, and up to 1L with milliQ water). The membrane is then blocked for 1 hour in blocking 
buffer (5% skim powdered milk in either 1x TBS-T or 1x TBS-A buffer). Afterwards the two parts of the 
membrane are washed three times for 5 minutes in 1x TBS-T or 1x TBS-A buffer. 
After washing the membrane the primary antibody is added (dilution 1:1000). For the determination of p-
P70S6K the primary antibody anti-p-P70S6K from Cell Signaling Technology (Danvers, MA, USA) is used. For the 
determination of P70S6K the primary antibody anti-P70S6K from Cell Signaling Technology (Danvers, MA, USA) 
is used. For the β-actin determination the primary antibody anti-β-actin from Cell Signaling Technology 
(Danvers, MA, USA) was used. The membrane overnights with the primary antibody on a rocking table at 4°C.  
 
Next day the membrane is washed three times for 5minutes in either 1x TBS-T or 1x TBS-A buffer. Then, the 
secondary antibody, anti-rabbit IgG: HRP-conjugate (Dako Denmark), was added and the membrane was 
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incubated for 1hour at room temperature. After incubation the membrane is washed again three times for 5 
minutes in either 1x TBS-T or 1x TBS-A buffer. 
 
Thereafter the membrane is developed with super signal liquid (Thermo Scientific). The two components of the 
liquid are mixed 1:1 and applied on top of the membrane and incubated for 2 minutes while covered. Excess 
liquid is dripped off and the membrane is put on a plastic foil and placed in the exposure cassette. The film is 
exposed to different times and developed.  The pictures of the membrane were developed with the UVP 
Biospectrum AC imagin system with Hama camera property of Roskilde University.  
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6. Results 
 
In this section the Western blot results for the different experiments are presented. Two main proteins have 
been detected for the assessment of mTOR activity, the phosphorylated and the non-phosphorylated 
ribosomal S6K (p-P70S6K and P70S6K respectively). β-actin has been used as a loading control. A control 
protein is the one that is expressed at a constant level because it is independent to the treatments.  β-actin has 
a molecular weight of 42KDa. 
The number and description of the experiments done in this project are given in the table below: 
 
Table 2. Total number of Western Blot analysis 
Number of experiments 24h resveratrol treatment 48h resveratrol treatment 
p-P70S6K determination 4 2 
P70S6K determination 1 1 
Total 8 Western Blot 
 
Each experiment result will be presented with a picture of the gel plus a band analysis of each of the lines. 
In this report it is only presented the most relevant results corresponding to 3 experiments from 24h treatment 
and 1 experiment from 48h treatment. The other experiments have not been included because the results are 
significantly influenced by a bad determination of the β-actin protein content giving no contribution to the 
project. However if the lector is interested in those results they are available by asking to the author of the 
report. 
5.1 24h treatment with resveratrol 
The effect of resveratrol on the level of p-p70S6K after 24h was measured in three separate experiments which 
were analyzed in separated western blot experiments. Further, the level of total p70S6K was analyzed in one 
set of the protein samples. Below, one set of the western blots are shown for p-p70S6K and p70S6K. 
For the band analysis the DMSO Control treatment was considered the reference band for both mutant and 
wild type cells. Band analysis quantification values are the ones corresponding to the adjusted density and they 
are presented in a column bar chart. These values correspond to the calculated relative protein content of p-
P70S6K or P70S6K taking into consideration the content of β-actin protein. For the control 10%DMSO adjusted 
density value is equal to 1. When no protein is observed the adjusted density has a value of 0.  
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Experiment 1 (1st determination of p-P70S6K) 
 
Gel picture: 
  
Figure 12. Upper part of the picture, determination of phosphorylated S6 kinase. Lower part, determination of the β-acting protein 
content. No bands observed for 0%FBS and rapamycin treatment. Clear higher intensity in the bands of the mutant cells. 
 
Table 3. Band analysis and adjusted density: 
 
 
In the wild type cells the level of p-P70S6K is lower than the control (DMSO). When comparing the adjusted 
densities it is possible to observe that the content of p-P70S6K is reduced by 46% in 10µM res treatment and 
20% in 30µM res treatment. No band is observed in 0%FBS treatment.  
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Exp 1. Adjusted density 
p-P70S6K 24h
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In the mutant cells it is possible to be detected some protein of the 0%FBS treatment. The intensity of the band 
of the mutant cells are much more intense that the bands in the wild type. No effect of resveratrol is observed 
in the mutant cells. No bands are observed for rapamycin treatment. Β-actin level is quite homogenous.  
Experiment 2 (2nd determination of p-P70S6K and 1st determination of total P70S6K) 
In this experiment the determination of p-P70S6K and the total protein determination of P70S6K has been 
done with the same cells, therefore results can be directly compared. 
 
Gel picture: 
p-P70S6K determination 
 
Figure 13. Upper part of the picture, determination of phosphorylated S6 kinase. Lower part of the picture, determination of the β-
acting protein content, irregular band intensity observed but still acceptable. No bands observed for 0%FBS wild type and rapamycin 
treatment. Clear higher intensity in the bands of the mutant cells. 
 
Table 4. Band analysis: 
p-P70S6K determination 
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In this experiment it is possible to detect again a reduction of p-P70S6K levels in the wild type cells when 
treated with resveratrol. The reduction is about 12% for 10µM res treatment and 17% for 30µM res treatment. 
No band is observed for 0%FBS and rapamycin treatment. 
In the wild type it is possible to observe a reduction of p-P70S6K level of 31% for 10µM res treatment and 27% 
in 30µM res treatment. In this experiment both wild type and mutant type have the same tendency. The level 
of protein in the 0%FBS mutant is much higher than control and that is a not expected result. 
Total P70S6K determination 
 
Gel picture: 
 
Figure 14. Upper part of the picture, determination of non-phosphorylated S6 kinase. Lower part of the picture, determination of the β-
acting protein content, regular band intensity observed. No bands observed for 0%FBS mutant type. No difference in band intensity 
between mutant and wild type cells. 
 
Table 5. Band analysis: 
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Calculated results from adjusted density for all the treatments are relative close to the control. That fits with 
the assumption that the amount of non-phosphorylated S6 kinase should be the same in all the lines because 
non-phosphorylated kinase is independent of the different treatments. Consequently the adjusted density 
value should be close to 1 in all the lines since there is no difference between protein content. Looking into the 
results, we can see that in effect there is almost the same amount of P70S6K in all the lines. That makes more 
reliable the results of the p-P70S6K determination in experiment 3. 
Experiment 3 (3rd determination of p-P70S6K) 
 
Gel picture: 
p-P70S6K determination 
 
Figure 15. Upper part of the picture, determination of phosphorylated S6 kinase. Lower part of the picture, determination of the β-
acting protein content, acceptable regularity in band intensity observed. No bands observed for 0%FBS wild type and rapamycin 
treatment. Clear higher intensity in the bands of the mutant cells. 
 
Table 6. Band analysis: 
p-P70S6K determination 
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Experiment 3 is the last experiment for 24h treatment. In this experiment it is possible to detect again a 
reduction of p-P70S6K levels in the wild type cells when treated with resveratrol. The reduction is about 47% 
for 10µM res treatment and 83% for 30µM res treatment. A little band is observed for 0%FBS and no band 
observed for rapamycin treatment. 
In the wild type the intensity of the bands are much higher. It is not possible to observe a clear reduction of p-
P70S6K level. In 10µM res treatment there is 5% more protein than in the control and for the 30µM res 
treatment there is a reduction of 9%. The level of protein in the 0%FBS mutant is 23% higher than in control. 
Again there is no band in rapamycin treated cells. 
5.2. 48h treatment with resveratrol 
In this section the results after 48h treatment will be presented in the same way 24h results has been 
presented. In total 2 experiments for p-P70S6K determination and 1 for P70S6K has been done. In this report 
only the results from one experiment are presented since the results for the second one are badly affected by 
an irregular determination of the β-actin content and therefore discarded in this report. 
For the band analysis, as in the 24h experiments, we have considered the DMSO Control treatment as the 
reference for both mutant and wild type cells. 
Experiment 1 (1st determination of p-P70S6K) 
Gel picture: 
p-P70S6K determination 
 
Figure 16. Upper part of the picture, determination of phosphorylated S6 kinase. Lower part of the picture, determination of the β-
acting protein content. Weak bands observed for 0%FBS wild type and no band observed for rapamycin treatment. Clear higher 
intensity in the bands of the mutant cells. 
 
  
Roskilde University  Page 27 
 
Table 7. Band analysis: 
 
 
These results after 48h treatment have the same tendency that the one presented for 24h treatment. In the 
wild type cells the level of p-P70S6K is lower than the control (DMSO). The content of p-P70S6K is reduced by 
30% in 10µM res treatment and by 55% in 30µM res treatment. A little band intensity is observed in 0%FBS 
treatment and no bands observed in rapamycin treatment. 
In the wild type the intensity of the bands are much higher. It is not possible to observe a clear reduction of p-
P70S6K level. In 10µM res treatment there is 7% more protein than in the control and for the 30µM res 
treatment there a reduction is of 9%. As observed in experiment 3 24h the level of protein in the 0%FBS mutant 
is much higher than in control. 
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7. Discussion 
 
In this section the main results of this project will be discussed. Fist the influence of having an irregular loading 
control will be treated since it has had a significant impact in the band quantification. Second the bands 
absence in 0%FBS treated cells since it has been an unexpected result. Third the difficulty of analyzing the 
mutant cell bands due to a high protein content. Fourth the interesting results obtained from the wild type 
cells and its relation with the effect of resveratrol in the mTOR pathway. Fifth I will try to connect the results of 
this project with anti-cancer studies form the literature.   
  
A significant difference in the intensity of the β-actin bands is generally observed in the experiments. This was a 
challenge when comparing band intensities of p-P70S6K and P70S6K. For a proper interpretation and reliability 
of the results the intensities of the β-actin bands would be expected to be regular in all the lines of the gel. In 
the literature there are some papers claiming that β-actin is not a reliable loading control protein in Western 
Blot because when higher amount of proteins are loaded (15µg) the anti-β-actin antibodies fails in detecting 
different levels of the actin protein (Dittmer and Dittmer, 2006). In this project the irregularity in the β-actin 
bands has cause problems during the analysis of the results since the adjusted density of the bands are based 
on the intensity of the β-actin bands. 
The level of protein in starved cells (0%FBS) are irregular and in many cases no protein is observed. The 
expected results would be less protein yield by starved cells compared the control (DSMO), but still some 
protein determination would be expected. In the results presented in this report we can observe an irregularity 
in the O%FBS band content. In experiment 3, 24h cells treatment, there is a very weak band in the 0%FBS line 
whereas in experiment 2, the band is non-existing or hardly perceivable.  The same occur with the 48h 
treatment cells where no band or almost no band is observed in the O%FBS line. In some cases this inexistence 
of band is observed in the β-acting part as well. That indicates that long term starved cells produce no protein 
(or not a detectable amount) and its usefulness should be considered for further experiments. However in the 
determination of the P70S6K it is possible to observe a band in the 0%FBS line in the wild type cells but not in 
the mutant. This is another sign of inconsistency when starved cells are used. Pipetting error during the 
Western Blot experimental work or cell culture preparation can be an extra parameter that can negatively 
influence in the results. 
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In TSC-/- cells it is possible to observe a significant increase in the intensity of the bands compared TSC+/+ cells. 
That is a higher yield of protein is obtained from mutant cells than from wild type cells.  TSC-/- permanently 
activates mTOR leading to higher amount of p-P70S6K. According the experimental results with mutant cells it 
is very difficult to observe any effect of resveratrol. Results from the 24h treatment are contradictory. In 
experiment 1 amount of p-P70S6K increase with resveratrol treatment, the band analysis indicates an increase 
of p-P70S6K of 2% in 10µM res cells and 25% in 30µM res cells. In experiment 2 the results show the opposite, 
the band analysis indicates a decrease of p-P70S6K of 31% in 10µM res cells and 27% in 30µM res cells. The 
results for the rest of the experiments are similar. Probably the yield of p-P70S6K in TSC-/- is so high that blind 
the possible effect of resveratrol. 
 
In TSC+/+ cells the intensity of the bands are much moderate. In the 24h experiments it is possible to observe 
an inhibitory effect of resveratrol in 3 different experiments. Especially relevant is experiment 2 where total 
P70S6K was also determined for the same cells. Here the band analysis indicates a reduction on the protein 
determination of  12% and 17% for 10µM and 30µM res treatment respectively. In experiment 3 the reduction 
of protein content is much bigger, 47% and 83% in 10µM and 30µM res treatment respectively. It can be 
several reasons for this difference, exact pipetting of the correct amounts of protein and β-actin determination 
are again possible factors for result deviation. Furthermore experimental error in Western Blot technique is 
high. However from these results is it possible to correlate with a certain degree of confidence the inhibitory 
effect of resveratrol in the mTOR activity. 
 
The effect of resveratrol in mTOR pathway has been treated in the literature by different authors. In cancer cell 
lines HeLa, HePG2 and MCF-7 resveratrol seemed to have an effect by down-regulating the expression of PKM2 
(Pyruvate Kinase M2) through the mTOR pathway. In this study the authors claims a reduction of PKM2 level 
after a treatment of 50µM resveratrol for 48h by Western Blot analysis and the reduction was quantified 
around 40-50% for the different cell lines. β-acting was used as a loading protein and rapamycin as control 
(Iqbal and Bamezai, 2012). The results presented in this project have certain similarities with the results 
presented by Iqbal et al. Here I have documented results that show decreased levels of p-P70S6K. Additionally 
Iqbal et al. worked with overexpressed level of PKM2 in mutated HeLa cells and claim reversal effect of 
resveratrol effect on PKM2 overexpression, mutation effect was stronger than the possible effect of 
resveratrol. This has certain analogy with the results of this project where it was not possible to see an effect of 
resveratrol for mutant TSC-/- because the high yield of protein. 
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Rapamycin has shown a strong and regular inhibitory effect of p-P70S6K in all the experiments. That indicates 
that rapamycin has a much stronger inhibitory effect than resveratrol. Only in the total protein determination 
of P70S6K we can observe that rapamycin has no effect. That proves the function of rapamycin inhibiting the 
phosphorylation of P70S6K, but it does not affect the level of P70S6K. 
 
The mechanisms by which resveratrol is inhibiting mTOR are not completely elucidated and different inhibitory 
pathways have been identified. However it is mostly accepted that resveratrol inhibits mTORC1 complex. Liu et 
al claims that resveratrol inhibits mTOR by increasing the affinity of mTOR with its inhibitor Deptor. Other 
studies points that in glioblastoma cells (brain tumor) resveratrol increase the production of ROS (reactive 
oxygen species) which at the same time activates AMPK (AMP-activated protein kinase) which is an inhibitor of 
mTOR (Yuan, et al., 2012). From the results presented in this project it is not possible to describe the exact 
inhibitory mechanism of resveratrol.  
 
It is important to consider the biological differences between mTORC1 and mTORC2. As described in the 
rapamycin section, rapamycin can inhibit mTORC1 but not mTORC2. What about resveratrol? In the literature it 
is possible to find a study with H9c2 cardiac myoblast with double findings. Fist it is claimed that resveratrol 
inhibits mTROC1. Second, they also claim that resveratrol positively induces the expression of Rictor in 
mTORC2 having as a consequence the activation of the Akt kinase. So in this case resveratrol has a dual 
function, as inhibitor of mTORC1 and as an activator of mTORC2 (Gurusamy, et al., 2010). This difference 
between mTORC1 and mTORC2 has led to further studies aiming at finding a single substance that can inhibit 
mTORC1 and mTORC2 at the same time, thus making treatments much more effective. In Acute Myeloid 
Leukemia cells (AML) a novel catalytic inhibitor (OSI-027) was found for both mTORC1 and mTORC2. OSI-027 
was more efficient in suppressing mRNA translation than rapamycin (Altman, et al., 2011). As discussed before 
the effect of resveratrol in mTORC1 has been partially proved, whether resveratrol has an impact in mTORC2 
cannot be discussed from the results of this project. 
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8. Conclusions 
Western Blot analysis has been used in this project for the determination of mTOR activity in MEF’s cells. The 
activity of mTOR has been quantified by the protein determination of p-P70S6K after different treatments. 
Band analysis for all the experiments has been done to quantify the intensity of the bands in the different gels. 
Visual and numerical results have been presented with an acceptable correlation between them.  
β-actin has not performed as a good loading protein since band intensities have been irregular in many of the 
experiment making difficult a good interpretation of the results. Bad gel loading, imprecise pipetting, 
differences in sample preparation, or bad primary antibody incubation can be possible reasons for the poor 
observed β -actin bands. 
In TSC+/+ cells it is possible to observe a certain correlation between the treatments with resveratrol and the 
inhibition of mTOR activiyt. Reduction of p-P70S6K protein after treatment with resveratrol has been 
quantified in a range from 12% to 83% for 10µM and 30µM res treatment respectively. The exact mechanism 
by which resveratrol inhibits mTOR is not elucidated. From TSC-/- cells no conclusion can be made. The 
irregular intensity of the β-actin bands has made very difficult the analysis and results are not reliable. No 
significant effect of resveratrol has been detected. Rapamycin clearly inhibits mTOR in both TSC+/+ and TSC-/- 
and this is correlated with results presented in the literature. 
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